SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 19, 2020
Akcea Therapeutics, Inc.
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction
|(Commission File Number)|| |
22 Boston Wharf Road
|(Address of Principal Executive Offices)||(Zip Code)|
Registrants Telephone Number, Including Area Code: (617) 207-0202
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
|Item 5.02|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Appointment of Damien McDevitt, Ph.D. to Chief Executive Officer
On March 24, 2020, Akcea Therapeutics, Inc. (the Company) announced the appointment of Damien McDevitt, Ph.D. to Chief Executive Officer of the Company, effective immediately. Dr. McDevitt has served as interim Chief Executive Officer of the Company since September 2019, as member of the Companys Board of Directors (Board) since October 2018 and will continue to serve as a member of the Board.
Dr. McDevitts career in executive management spans more than 30 years, including most recently as chief business officer for Ionis Pharmaceuticals, Inc. Prior to Ionis, he was a senior vice president at ACADIA Pharmaceuticals. Prior to ACADIA, Dr. McDevitt was with GSK for more than two decades. He served on both the R&D Technology Investment Board and the Infectious Disease Therapy Area Unit Board, providing input to critical R&D investments for over 10 years. He served in various leadership roles within R&D and was head of GSKs R&D West Coast Innovation Center. He also worked in Worldwide Business Development, GSK Ventures and in anti-infective discovery. Dr. McDevitt is an author of 70 scientific publications and published patents. He attended Trinity College in Dublin, Ireland, where he earned his Ph.D. and undergraduate degree, both in microbiology.
In connection with Dr. McDevitts appointment to Chief Executive Officer of the Company, Dr. McDevitt will receive:
An annual base salary of $650,000; and
A stock option exercisable for up to 200,000 shares of the Companys common stock, vesting over a four-year period, under the Companys 2015 Equity Incentive Plan.
There are no family relationships between Dr. McDevitt and any director or executive officer of the Company, and Dr. McDevitt is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
The foregoing description of the 2015 Equity Incentive Plan does not purport to be complete and is qualified in its entirety by the full text of the 2015 Equity Incentive Plan, a copy of which is filed as Exhibit 10.2 to the Companys Current Report on Form 8-K filed September 5, 2017, which is incorporated into this Item 5.02 by reference herein.
A copy of the Companys press release regarding Dr. McDevitts appointment to Chief Executive Officer of the Company is attached hereto as Exhibit 99.1.
|Item 9.01.|| |
Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|AKCEA THERAPEUTICS, INC.|
|Date: March 24, 2020||By:||/s/ Joshua F. Patterson|
|Joshua F. Patterson|
Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
BOSTON, March 24, 2020 (GLOBE NEWSWIRE) Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that its board of directors has appointed Damien McDevitt, Ph.D. as Chief Executive Officer, effective immediately. Dr. McDevitt has served as interim CEO of Akcea since September 2019 and will continue to serve as a member of the Akcea board of directors.
With his experience at both Ionis and Akcea, Damien has the perspective and insight to lead Akcea at a time when the company is positioned to make rapid progress in advancing its global development and commercialization strategies, said B. Lynne Parshall, J.D., chairman of the board at Akcea. Damien has led the company through a transformational period where it has expanded the senior leadership team, announced a global licensing deal for AKCEA-ANGPTL3-LRx, advanced its international commercialization strategies for TEGSEDI and WAYLIVRA, and made significant progress in building the pipeline.
Dr. McDevitts career spans more than 30 years, including most recently as chief business officer for Ionis Pharmaceuticals. Prior to Ionis, he was a senior vice president at ACADIA Pharmaceuticals. Prior to ACADIA, Dr. McDevitt was with GSK for more than two decades. He served on both the R&D Technology Investment Board and the Infectious Disease Therapy Area Unit Board, providing input to critical R&D investments for over 10 years. He served in various leadership roles within R&D and was head of GSKs R&D West Coast Innovation Center. He also worked in Worldwide Business Development, GSK Ventures and in anti-infective discovery. Dr. McDevitt is an author of 70 scientific publications and published patents. He attended Trinity College in Dublin, Ireland, where he earned his Ph.D. and undergraduate degree, both in microbiology.
Over the past few months, I have seen firsthand the outstanding capabilities of the Akcea team in advancing our global commercialization and development strategies as well as our unsurpassed level of commitment to making a positive difference for patients affected by serious and rare diseases, Dr. McDevitt said, adding, I am very honored to serve this organization full of energetic and talented people and innovative therapies, and look forward to continuing to build upon Akceas successes, as we plan for many important developments in the years ahead.
ABOUT AKCEA THERAPEUTICS
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI® (inotersen) and WAYLIVRA® (volanesorsen), as well as advancing a mature pipeline of novel drugs, including AKCEA-APO(a)-LRx, AKCEA-
ANGPTL3-LRx, AKCEA-APOCIII-LRx, and AKCEA-TTR-LRx, with the potential to treat multiple diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil. WAYLIVRA is approved in the E.U. and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Boston, Massachusetts. Additional information about Akcea is available at www.akceatx.com and you can follow us on Twitter at @akceatx.
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akceas goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of Akceas drugs in development is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akceas forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akceas forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akceas programs are described in additional detail in Akceas quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the SEC. Copies of these and other documents are available from the company.
In this press release, unless the context requires otherwise, Ionis, Akcea, Company, Companies, we, our, and us refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals is a trademark of Ionis Pharmaceuticals, Inc., Akcea Therapeutics®, TEGSEDI® and WAYLIVRA® are trademarks of Akcea Therapeutics, Inc.
Senior Director of Corporate Communications
Akcea Media Contact:
Berry & Company
T: 212 253-8881